COVID-19 Information

Ensuring Access and Supply of Our Medicines

We are maintaining a regular supply of our medicines to patients around the world as our manufacturing and distribution sources continue to function normally. In the event supply chains were disrupted for any reason, we do not anticipate a shortage of our medicines due to ample inventory levels.

Patients who have questions or concerns about their treatment should consult with their doctor, and can also contact UltraCare® at 1-888-756-8657, Monday through Friday 9AM - 8PM ET or by email at ultracare@ultragenyx.com.

Continuing Our Clinical Studies

For patients in our clinical trials receiving investigational treatment, we do not foresee any interruptions to continued supply. We continue to monitor the evolving situation in support of clinical trial sites and patients participating in our studies.

Supporting Our Workforce and Our Community

We have put measures in place to prepare for and protect against the transmission of COVID-19 in our offices and our community, while ensuring the critical work required to bring our medicines to patients continues.

• We are followng regional guidelines and taking a conservative approach to returning employees into the workplace. This includes employees at all of our offices throughout the world.
• We have enhanced cleaning procedures at all office locations and routine COVID testing to help protect those who continue to work onsite.
• We are following regional guidelines and providing our employees options on in-person attendance at meetings and other larger gatherings.

Safe Harbor

This business update includes forward-looking statements based on our current expectations and beliefs that are subject to risks and uncertainties. Our actual results may differ materially. Please consult the risk factors section of our SEC filings.

Continuing our Clinical Studies

For patients in our clinical trials receiving investigational treatment, we do not foresee any interruptions to continued supply. We continue to monitor the evolving situation in support of clinical trial sites and patients participating in our studies.